Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $21,940.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the business's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $10.97, for a total value of $21,940.00. Following the sale, the president now owns 2,808,824 shares of the company's stock, valued at $30,812,799.28. The trade was a 0.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Friday, May 23rd, Songjiang Ma sold 182 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.24, for a total value of $1,863.68.
• On Wednesday, March 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.13, for a total value of $20,260.00.
• On Monday, March 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.09, for a total value of $24,180.00.
• On Friday, March 14th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.31, for a total value of $24,620.00.
• On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.74, for a total value of $23,480.00.
• On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.14, for a total transaction of $20,280.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.25, for a total transaction of $20,500.00.

Gyre Therapeutics Trading Down 3.8%

NASDAQ GYRE traded down $0.36 during mid-day trading on Friday, reaching $9.10. 231,034 shares of the company's stock traded hands, compared to its average volume of 115,115. Gyre Therapeutics, Inc. has a 1-year low of $6.11 and a 1-year high of $19.00. The company has a fifty day simple moving average of $8.96 and a 200-day simple moving average of $10.51. The company has a market cap of $853.20 million, a price-to-earnings ratio of 455.00 and a beta of 1.90.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported $0.03 EPS for the quarter, meeting analysts' consensus estimates of $0.03. The firm had revenue of $22.06 million for the quarter, compared to the consensus estimate of $28.40 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.

Wall Street Analysts Forecast Growth

Separately, Noble Financial started coverage on shares of Gyre Therapeutics in a research report on Tuesday, March 11th. They issued an "outperform" rating for the company.

Institutional Trading of Gyre Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. SBI Securities Co. Ltd. bought a new stake in Gyre Therapeutics in the fourth quarter valued at about $1,225,000. Barclays PLC increased its holdings in Gyre Therapeutics by 13.5% in the fourth quarter. Barclays PLC now owns 10,543 shares of the company's stock valued at $128,000 after buying an additional 1,255 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Gyre Therapeutics by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after buying an additional 913 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Gyre Therapeutics by 11.1% in the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company's stock valued at $168,000 after buying an additional 1,389 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in Gyre Therapeutics by 9.1% in the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company's stock valued at $1,251,000 after buying an additional 8,624 shares during the last quarter. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.